Total available patients screened for enrollment (n = 38)

- Screening failure (n = 2)
- Excluded due to anemia under surgery (n = 1)
- Withdrew consent (n = 1)
- Diagnosis of bladder cancer (n = 1)

33 patients enrolled

- No baseline plasma sample available (n = 3)

30 patients

- Death post surgery (n = 4)
- No follow-up (n = 3)

21 patients with tumor biopsy samples, pretreatment plasma and serial plasma samples

Withdrawn consent (n = 1)
Supplementary Figure 2

A

KRAS G12D

EGFR del19 (E746-A750)

PIK3CA E545K

NRAS A59T

Expected AF (%, log)

Observed AF (%, log)

Expected AF (%, log)

Observed AF (%, log)

Expected AF (%, log)

Observed AF (%, log)

B

6 false positive results
Specificity = 95%

Mean AF (%, log)

N.D.

Mean AF threshold

n = 126 tests
Supplementary Figure 3

Stage I+II
Stage III

ctDNA mean VAF during surgery (%)

mean = 0.09
mean = 0.15

p = 0.07

n.d.
n = 10
n = 9
Supplementary Figure 4

A

Progression-free survival (%)

- during surgery ctDNA - (n = 8)
- during surgery ctDNA + (n = 11)

p = 0.24
HR = 0.47 (95% CI = 0.14-1.66)

Time in months

B

Overall survival (%)

- during surgery ctDNA - (n = 8)
- during surgery ctDNA + (n = 11)

p = 0.19
HR = 0.34 (95% CI = 0.069-1.73)

Time in months